Examining Endothelial Dysfunction and The Effect of Topical
Treatment with Prostaglandin E1 In Diabetics Suffering from
Erectile Dysfunction

J 2020

Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction

ŠRÁMKOVÁ, Taťána; K. ŠRÁMKOVÁ; Jiří JARKOVSKÝ; Michal POHANKA; Aleš ČERMÁK et. al.

Basic information

Original name

Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction

Authors

ŠRÁMKOVÁ, Taťána; K. ŠRÁMKOVÁ; Jiří JARKOVSKÝ ; Michal POHANKA and Aleš ČERMÁK

Edition

Biomedical Journal of Scientific & Technical Research, Westchester, Biomedical Research Network, 2020, 2574-1241

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30217 Urology and nephrology

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

RIV identification code

RIV/00216224:14110/20:00117461

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.26717/BJSTR.2020.26.004386

Keywords in English

Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score

Abstract

In the original language

Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.

Cite

ŠRÁMKOVÁ, Taťána; K. ŠRÁMKOVÁ; Jiří JARKOVSKÝ; Michal POHANKA and Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. Biomedical Journal of Scientific & Technical Research. Westchester: Biomedical Research Network, 2020, vol. 26, No 4, p. 20160-20166. ISSN 2574-1241. Available from: https://doi.org/10.26717/BJSTR.2020.26.004386.

@article{1713418,
   author = {Šrámková, Taťána and Šrámková, K. and Jarkovský, Jiří and Pohanka, Michal and Čermák, Aleš},
   article_location = {Westchester},
   article_number = {4},
   doi = {https://doi.org/10.26717/BJSTR.2020.26.004386},
   keywords = {Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score},
   language = {eng},
   issn = {2574-1241},
   journal = {Biomedical Journal of Scientific & Technical Research},
   title = {Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction},
   url = {https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php},
   volume = {26},
   year = {2020}
}

TY  - JOUR
ID  - 1713418
AU  - Šrámková, Taťána - Šrámková, K. - Jarkovský, Jiří - Pohanka, Michal - Čermák, Aleš
PY  - 2020
TI  - Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction
JF  - Biomedical Journal of Scientific & Technical Research
VL  - 26
IS  - 4
SP  - 20160-20166
EP  - 20160-20166
PB  - Biomedical Research Network
SN  - 25741241
KW  - Erectile Dysfunction
KW  - Diabetes Type 2
KW  - Endothelial Dysfunction
KW  - Topical Alprostadil
KW  - International Index of Erectile Function
KW  - Erectile Hardness Score
UR  - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
L2  - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
N2  - Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.
ER  -

ŠRÁMKOVÁ, Taťána; K. ŠRÁMKOVÁ; Jiří JARKOVSKÝ; Michal POHANKA and Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. \textit{Biomedical Journal of Scientific \&{} Technical Research}. Westchester: Biomedical Research Network, 2020, vol.~26, No~4, p.~20160-20166. ISSN~2574-1241. Available from: https://doi.org/10.26717/BJSTR.2020.26.004386.

Přehled o publikaci